Parallel Advisors’s Unity Biotechnology UBX Stock Holding History

Parallel Advisors’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	3300
2021 Q3	$0	Hold	1	–	–	﹤0.01%	3271
2021 Q2	$0	Hold	1	–	–	﹤0.01%	3068
2021 Q1	$0	Hold	1	–	–	﹤0.01%	2904
2020 Q4	$0	Buy	+1	New	+$48	﹤0.01%	2730

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Parallel Advisors's UBX Position: Q4 2021 in Review

Parallel Advisors sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 1 share.

Parallel Advisors first reported a position in UBX in Q4 2020 and held it in 4 quarters. The position peaked at $0 in Q3 2021. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

Parallel Advisors reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
Parallel Advisors sold 1 Unity Biotechnology share in Q4 2021.
Parallel Advisors first reported a position in Unity Biotechnology in Q4 2020 and held it in 4 quarters.
Parallel Advisors's Unity Biotechnology position peaked at $0 in Q3 2021.
71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.